Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in diffuse large B-cell lymphoma: Updated analysis of waveline-007

View Full Paper
Ask AI
Bookmark
Share

Authors

YVYulia VolchekSheba Medical CenterRCRaúl CórdobaHospital Universitario Fundación Jiménez DíazBPBenedetta PucciniAzienda Ospedaliero-Universitaria Careggi

Discussion

Loading...

Member takes

Implication

Phase 2 trial demonstrates a 97.2% complete response rate in DLBCL patients receiving zilovertamab vedotin with R-CHP, implying robust efficacy and safety profiles.

Key Points

  • To evaluate the safety and efficacy of zilovertamab vedotin in combination with R-CHP in patients with diffuse large B-cell lymphoma (DLBCL).
  • Phase 2 trial with participants aged ≥18 years having untreated DLBCL confirmed by imaging.
  • Participants received ZV plus R-CHP every 3 weeks for 6 or 8 cycles.
  • Endpoints included safety, recommended phase 2 dose (RP2D), and complete response (CR) rates according to Lugano criteria.
  • All participants receiving ZV 1.75 mg/kg achieved complete response (CR) with an overall CR rate of 97.2%.
  • The objective response rate (ORR) was 100% across ZV doses.
  • Treatment-related adverse events occurred in all participants, with neutropenia being the most common.

Cite This Study

Volchek et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4f0https://doi.org/10.1182/blood-2025-5516
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-0032025 · 1 citations
  2. 2Zilovertamab vedotin plus R-CHP versus R-CHOP for first-line treatment of diffuse large B-cell lymphoma: The phase 3 waveline-010 study2025 · 1 citations
  3. 3waveLINE-011: Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in germinal center B-cell–like (GCB) diffuse large B-cell lymphoma (DLBCL).2026
  4. 4Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study2025 · 1 citations
  5. 5Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025 · 7 citations